abstract |
The present invention provides a nucleic acid encoding IFN-α fusion proteins. The specification also describes the proteins encoded by said nucleic acids, methods of making IFN-α fusion proteins and methods of utilizing the compounds for the treatment of cancer. One specific IFN-α fusion protein comprising IFN-α or a portion thereof capable of enhancing the killing ability of an effector cell and an anti-CD20 antibody, such as RITUXAN®, which can target, for example, B cell lymphomas (e.g., non-Hodgkin's lymphoma). |